Skip to main content
Top
Published in: The Journal of Headache and Pain 1/2017

Open Access 01-12-2017 | Research article

Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design

Authors: Daniel Serrano, Richard B. Lipton, Ann I. Scher, Michael L. Reed, Walter (Buzz) F. Stewart, Aubrey Manack Adams, Dawn C. Buse

Published in: The Journal of Headache and Pain | Issue 1/2017

Login to get access

Abstract

Background

Relatively little is known about the stability of a diagnosis of episodic migraine (EM) or chronic migraine (CM) over time. This study examines natural fluctuations in self-reported headache frequency as well as the stability and variation in migraine type among individuals meeting criteria for EM and CM at baseline.

Methods

The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study was a longitudinal survey of US adults with EM and CM identified by a web-questionnaire. A validated questionnaire was used to classify respondents with EM (<15 headache days/month) or CM (≥15 headache days/month) every three months for a total of five assessments. We described longitudinal persistence of baseline EM and CM classifications. In addition, we modelled longitudinal variation in headache day frequency per month using negative binomial repeated measures regression models (NBRMR).

Results

Among the 5464 respondents with EM at baseline providing four or five waves of data, 5048 (92.4%) had EM in all waves and 416 (7.6%) had CM in at least one wave. Among 526 respondents with CM at baseline providing four or five waves of data, 140 (26.6%) had CM in every wave and 386 (73.4%) had EM for at least one wave. Individual plots revealed striking within-person variations in headache days per month. The NBRMR model revealed that the rate of headache days increased across waves of observation 19% more per wave for CM compared to EM (rate ratio [RR], 1.19; 95% CI, 1.13–1.26). After adjustment for covariates, the relative difference changed to a 26% increase per wave (RR, 1.26; 95% CI, 1.2–1.33).

Conclusions

Follow-up at three-month intervals reveals a high level of short-term variability in headache days per month. As a consequence, many individuals cross the CM diagnostic boundary of ≥15 headache days per month.Nearly three quarters of persons with CM at baseline drop below this diagnostic boundary at least once over the course of a year. These findings are of interest in the consideration of headache classification and diagnosis, the design and interpretation of epidemiologic and clinical studies, and clinical management.
Appendix
Available only for authorised users
Literature
1.
go back to reference Headache Classification Committee of the International Headache Society (2013) The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 33:629–808. doi:10.1177/0333102413485658 Headache Classification Committee of the International Headache Society (2013) The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 33:629–808. doi:10.​1177/​0333102413485658​
2.
go back to reference Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M (2001) Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 41:646–657 Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M (2001) Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 41:646–657
3.
go back to reference Buse DC, Manack AN, Fanning KM, Serrano D, Reed ML, Turkel CC, Lipton RB (2012) Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache 52:1456–1470. doi:10.1111/j.1526-4610.2012.02223.x Buse DC, Manack AN, Fanning KM, Serrano D, Reed ML, Turkel CC, Lipton RB (2012) Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache 52:1456–1470. doi:10.​1111/​j.​1526-4610.​2012.​02223.​x
4.
go back to reference Blumenfeld AM, Varon SF, Wilcox TK, Buse DC, Kawata AK, Manack A, Goadsby PJ, Lipton RB (2011) Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia 31:301–315. doi:10.1177/0333102410381145 Blumenfeld AM, Varon SF, Wilcox TK, Buse DC, Kawata AK, Manack A, Goadsby PJ, Lipton RB (2011) Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia 31:301–315. doi:10.​1177/​0333102410381145​
5.
go back to reference Payne KA, Varon SF, Kawata AK, Yeomans K, Wilcox TK, Manack A, Buse DC, Lipton RB, Goadsby PJ, Blumenfeld AM (2011) The International Burden of Migraine Study (IBMS): study design, methodology, and baseline cohort characteristics. Cephalalgia 31:1116–1130. doi:10.1177/0333102411410610 Payne KA, Varon SF, Kawata AK, Yeomans K, Wilcox TK, Manack A, Buse DC, Lipton RB, Goadsby PJ, Blumenfeld AM (2011) The International Burden of Migraine Study (IBMS): study design, methodology, and baseline cohort characteristics. Cephalalgia 31:1116–1130. doi:10.​1177/​0333102411410610​
6.
go back to reference Lipton RB, Manack Adams A, Buse DC, Fanning KM, Reed ML (2016) A comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: demographics and headache-related disability. Headache 56:1280–1289 Lipton RB, Manack Adams A, Buse DC, Fanning KM, Reed ML (2016) A comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: demographics and headache-related disability. Headache 56:1280–1289
7.
8.
go back to reference Manack Adams A, Serrano D, Buse DC, Reed ML, Marske V, Fanning KM, Lipton RB (2015) The impact of chronic migraine: the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results. Cephalalgia 35:563–578. doi:10.1177/0333102414552532 Manack Adams A, Serrano D, Buse DC, Reed ML, Marske V, Fanning KM, Lipton RB (2015) The impact of chronic migraine: the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results. Cephalalgia 35:563–578. doi:10.​1177/​0333102414552532​
9.
go back to reference Silberstein SD, Lipton RB, Sliwinski M (1996) Classification of daily and near-daily headaches: field trial of revised IHS criteria. Neurology 47:871–875CrossRefPubMed Silberstein SD, Lipton RB, Sliwinski M (1996) Classification of daily and near-daily headaches: field trial of revised IHS criteria. Neurology 47:871–875CrossRefPubMed
10.
go back to reference Buse DC, Manack AN, Serrano D, Reed ML, Varon S, Turkel CC, Lipton RB (2012) Headache impact of chronic and episodic migraine: results from the American Migraine Prevalence and Prevention study. Headache 52:3-17. doi:10.1111/j.1526-4610.2011.02046.x Buse DC, Manack AN, Serrano D, Reed ML, Varon S, Turkel CC, Lipton RB (2012) Headache impact of chronic and episodic migraine: results from the American Migraine Prevalence and Prevention study. Headache 52:3-17. doi:10.​1111/​j.​1526-4610.​2011.​02046.​x
12.
go back to reference Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB (2008) Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 48:1157–1168. doi:10.1111/j.1526-4610.2008.01217.x Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB (2008) Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 48:1157–1168. doi:10.​1111/​j.​1526-4610.​2008.​01217.​x
13.
go back to reference Aamodt AH, Stovner LJ, Langhammer A, Hagen K, Zwart JA (2007) Is headache related to asthma, hay fever, and chronic bronchitis? The Head-HUNT Study. Headache 47:204–212 Aamodt AH, Stovner LJ, Langhammer A, Hagen K, Zwart JA (2007) Is headache related to asthma, hay fever, and chronic bronchitis? The Head-HUNT Study. Headache 47:204–212
14.
go back to reference Linde M, Stovner LJ, Zwart JA, Hagen K (2011) Time trends in the prevalence of headache disorders. The Nord-Trondelag Health Studies (HUNT 2 and HUNT 3). Cephalalgia. doi:10.1177/0333102410391488 Linde M, Stovner LJ, Zwart JA, Hagen K (2011) Time trends in the prevalence of headache disorders. The Nord-Trondelag Health Studies (HUNT 2 and HUNT 3). Cephalalgia. doi:10.​1177/​0333102410391488​
17.
go back to reference Stewart WF, Wood GC, Bruce C, Buse DC, Runken MC, Lipton RB (2011) Longitudinal change in migraine headache-days and indirect cost consequences. J Occup Environ Med 53:478–487CrossRefPubMed Stewart WF, Wood GC, Bruce C, Buse DC, Runken MC, Lipton RB (2011) Longitudinal change in migraine headache-days and indirect cost consequences. J Occup Environ Med 53:478–487CrossRefPubMed
18.
go back to reference Lipton RB (2009) Tracing transformation: chronic migraine classification, progression, and epidemiology. Neurology 72:S3–S7CrossRefPubMed Lipton RB (2009) Tracing transformation: chronic migraine classification, progression, and epidemiology. Neurology 72:S3–S7CrossRefPubMed
19.
20.
go back to reference Silberstein S, Tfelt-Hansen P, Dodick DW, Limmroth V, Lipton RB, Pascual J, Wang SJ (2008) Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia 28:484-495. doi:10.1111/j.1468-2982.2008.01555.x Silberstein S, Tfelt-Hansen P, Dodick DW, Limmroth V, Lipton RB, Pascual J, Wang SJ (2008) Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia 28:484-495. doi:10.​1111/​j.​1468-2982.​2008.​01555.​x
21.
go back to reference Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30:793–803. doi:10.1177/0333102410364676 CrossRefPubMed Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30:793–803. doi:10.​1177/​0333102410364676​ CrossRefPubMed
22.
go back to reference Bigal ME, Edvinsson L, Rapoport AM, Lipton RB, Spierings EL, Diener HC, Burstein R, Loupe PS, Ma Y, Yang R, Silberstein SD (2015) Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 14:1091–1100CrossRefPubMed Bigal ME, Edvinsson L, Rapoport AM, Lipton RB, Spierings EL, Diener HC, Burstein R, Loupe PS, Ma Y, Yang R, Silberstein SD (2015) Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 14:1091–1100CrossRefPubMed
23.
go back to reference Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF (2010) OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 50:921-936. doi:10.1111/j.1526-4610.2010.01678.x Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF (2010) OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 50:921-936. doi:10.​1111/​j.​1526-4610.​2010.​01678.​x
24.
go back to reference Silberstein S, Lipton R, Dodick D, Freitag F, Mathew N, Brandes J, Bigal M, Ascher S, Morein J, Wright P, Greenberg S, Hulihan J (2009) Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache 49:1153–1162. doi:10.1111/j.1526-4610.2009.01508.x CrossRefPubMed Silberstein S, Lipton R, Dodick D, Freitag F, Mathew N, Brandes J, Bigal M, Ascher S, Morein J, Wright P, Greenberg S, Hulihan J (2009) Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache 49:1153–1162. doi:10.​1111/​j.​1526-4610.​2009.​01508.​x CrossRefPubMed
25.
go back to reference Stovner LJ, Linde M, Gravdahl GB, Tronvik E, Aamodt AH, Sand T, Hagen K (2014) A comparative study of candesartan versus propranolol for migraine prophylaxis: a randomised, triple-blind, placebo-controlled, double cross-over study. Cephalalgia 34:523–532CrossRefPubMed Stovner LJ, Linde M, Gravdahl GB, Tronvik E, Aamodt AH, Sand T, Hagen K (2014) A comparative study of candesartan versus propranolol for migraine prophylaxis: a randomised, triple-blind, placebo-controlled, double cross-over study. Cephalalgia 34:523–532CrossRefPubMed
Metadata
Title
Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design
Authors
Daniel Serrano
Richard B. Lipton
Ann I. Scher
Michael L. Reed
Walter (Buzz) F. Stewart
Aubrey Manack Adams
Dawn C. Buse
Publication date
01-12-2017
Publisher
Springer Milan
Published in
The Journal of Headache and Pain / Issue 1/2017
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI
https://doi.org/10.1186/s10194-017-0787-1

Other articles of this Issue 1/2017

The Journal of Headache and Pain 1/2017 Go to the issue